Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 5/2018

Open Access 01-10-2018 | PRECLINICAL STUDIES

Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide

Authors: Ruud Oerlemans, Celia R. Berkers, Yehuda G. Assaraf, George L. Scheffer, Godefridus J. Peters, Sue Ellen Verbrugge, Jacqueline Cloos, Jerry Slootstra, Rob H. Meloen, Robert H. Shoemaker, Ben A. C. Dijkmans, Rik J. Scheper, Huib Ovaa, Gerrit Jansen

Published in: Investigational New Drugs | Issue 5/2018

Login to get access

Summary

Background The hexapeptide 4A6 (Ac-Thr(tBu)-His(Bzl)-Thr(Bzl)-Nle-Glu(OtBu)-Gly-Bza) was isolated from a peptide library constructed to identify peptide-based transport inhibitors of multidrug resistance (MDR) efflux pumps including P-glycoprotein and Multidrug Resistance-associated Protein 1. 4A6 proved to be a substrate but not an inhibitor of these MDR efflux transporters. In fact, 4A6 and related peptides displayed potent cytotoxic activity via an unknown mechanism. Objective To decipher the mode of cytotoxic activity of 4A6. Methods Screening of 4A6 activity was performed against the NCI60 panel of cancer cell lines. Possible interactions of 4A6 with the 26S proteasome were assessed via proteasome activity and affinity labeling, and cell growth inhibition studies with leukemic cells resistant to the proteasome inhibitor bortezomib (BTZ). Results The NCI60 panel COMPARE analysis revealed that 4A6 had an activity profile overlapping with BTZ. Consistently, 4A6 proved to be a selective and reversible inhibitor of β5 subunit (PSMB5)-associated chymotrypsin-like activity of the 26S proteasome. This conclusion is supported by several lines of evidence: (i) inhibition of chymotrypsin-like proteasome activity by 4A6 and related peptides correlated with their cell growth inhibition potencies; (ii) 4A6 reversibly inhibited functional β5 active site labeling with the affinity probe BodipyFL-Ahx3L3VS; and (iii) human myeloid THP1 cells with acquired BTZ resistance due to mutated PSMB5 were highly (up to 287-fold) cross-resistant to 4A6 and its related peptides. Conclusion 4A6 is a novel specific inhibitor of the β5 subunit-associated chymotrypsin-like proteasome activity. Further exploration of 4A6 as a lead compound for development as a novel proteasome-targeted drug is warranted.
Literature
1.
Adams J (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5:417–421CrossRefPubMed
2.
Richardson PG, Mitsiades C, Hideshima T, Anderson KC (2006) Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57:33–47CrossRefPubMed
3.
Voorhees PM, Orlowski RZ (2006) The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 46:189–213CrossRefPubMed
4.
Gatti L, Zuco V, Zaffaroni N, Perego P (2013) Drug combinations with proteasome inhibitors in antitumor therapy. Curr Pharm Des 19:4094–4114CrossRefPubMed
5.
Van der Heijden JW, Oerlemans R, Lems WF, Scheper RJ, Dijkmans BA, Jansen G (2009) The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. Clin Exp Rheumatol 27:92–98PubMed
6.
Dick LR, Fleming PE (2010) Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 15:243–249CrossRefPubMed
7.
Anderson KC (2012) The 39th David A. Karnofsky lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol 30:445–452CrossRefPubMed
8.
Verbrugge SE, Scheper RJ, Lems WF, de Gruijl TD, Jansen G (2015) Proteasome inhibitors as experimental therapeutics of autoimmune diseases. Arthritis Res Ther 17:17CrossRefPubMedPubMedCentral
9.
10.
Cloos J, Roeten MS, Franke NE, van Meerloo J, Zweegman S, Kaspers GJ, Jansen G (2017) (Immuno) proteasomes as therapeutic target in acute leukemia. Cancer Metastasis Rev 36:599–615CrossRefPubMedPubMedCentral
11.
12.
Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373–428CrossRefPubMed
13.
Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E (2016) Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget 7:6521–6537PubMed
14.
Kisselev AF, Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8:739–758CrossRefPubMed
15.
Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8:407–419CrossRefPubMed
16.
Borissenko L, Groll M (2007) 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev 107:687–717CrossRefPubMed
17.
18.
Niewerth D, Dingjan I, Cloos J, Jansen G, Kaspers G (2013) Proteasome inhibitors in acute leukemia. Expert Rev Anticancer Ther 13:327–337CrossRefPubMed
19.
20.
Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120:947–959CrossRefPubMedPubMedCentral
21.
Kisselev AF, Callard A, Goldberg AL (2006) Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 281:8582–8590CrossRefPubMed
22.
Argyriou AA, Iconomou G, Kalofonos HP (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112:1593–1599CrossRefPubMed
23.
McConkey DJ, Zhu K (2008) Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 11:164–179CrossRefPubMed
24.
Niewerth D, Jansen G, Assaraf YG, Zweegman S, Kaspers GJ, Cloos J (2015) Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Updat 18:18–35CrossRefPubMed
25.
Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P (2007) Proteasome inhibitors: antitumor effects and beyond. Leukemia 21:30–36CrossRefPubMed
26.
Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67:6383–6391CrossRefPubMed
27.
Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110:3281–3290CrossRefPubMedPubMedCentral
28.
Orlowski RZ, Kuhn DJ (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14:1649–1657CrossRefPubMed
29.
Kuhn DJ, Orlowski RZ (2012) The immunoproteasome as a target in hematologic malignancies. Semin Hematol 49:258–262CrossRefPubMed
30.
Huber EM, Basler M, Schwab R, Heinemeyer W, Kirk CJ, Groettrup M, Groll M (2012) Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 148:727–738CrossRefPubMed
31.
Huber EM, Groll M (2012) Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development. Angew Chem Int Ed Eng 51:8708–8720CrossRef
32.
de Jong MC, Slootstra JW, Scheffer GL, Schroeijers AB, Puijk WC, Dinkelberg R, Kool M, Broxterman HJ, Meloen RH, Scheper RJ (2001) Peptide transport by the multidrug resistance protein MRP1. Cancer Res 61:2552–2557PubMed
33.
Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219–234CrossRefPubMed
34.
Caetano-Pinto P, Jansen J, Assaraf YG, Masereeuw R (2017) The importance of breast cancer resistance protein to the kidneys excretory function and chemotherapeutic resistance. Drug Resist Updat 30:15–27CrossRefPubMed
35.
Li W, Zhang H, Assaraf YG, Zhao K, Xu X, Xie J, Yang DH, Chen ZS (2016) Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updat 27:14–29CrossRefPubMed
36.
Shapira A, Livney YD, Broxterman HJ, Assaraf YG (2011) Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat 14:150–163CrossRefPubMed
37.
Sharom FJ, Yu X, Diodato G, Chu JW (1996) Synthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport. Biochem J 320(Pt 2):421–428CrossRefPubMedPubMedCentral
38.
Sharom FJ, Yu X, Lu P, Liu R, Chu JW, Szabo K, Muller M, Hose CD, Monks A, Varadi A, Seprodi J, Sarkadi B (1999) Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. Biochem Pharmacol 58:571–586CrossRefPubMed
39.
Daoud SS, Juliano RL (1989) Modulation of doxorubicin resistance by valinomycin (NSC 122023) and liposomal valinomycin in Chinese hamster ovary cells. Cancer Res 49:2661–2667PubMed
40.
Assaraf YG, Borgnia MJ (1994) Probing the interaction of the multidrug-resistance phenotype with the polypeptide ionophore gramicidin D via functional channel formation. Eur J Biochem 222:813–824CrossRefPubMed
41.
Toppmeyer DL, Slapak CA, Croop J, Kufe DW (1994) Role of P-glycoprotein in dolastatin 10 resistance. Biochem Pharmacol 48:609–612CrossRefPubMed
42.
Sarkadi B, Muller M, Homolya L, Hollo Z, Seprodi J, Germann UA, Gottesman MM, Price EM, Boucher RC (1994) Interaction of bioactive hydrophobic peptides with the human multidrug transporter. FASEB J 8:766–770CrossRefPubMed
43.
Eytan GD, Borgnia MJ, Regev R, Assaraf YG (1994) Transport of polypeptide ionophores into proteoliposomes reconstituted with rat liver P-glycoprotein. J Biol Chem 269:26058–26065PubMed
44.
Borgnia MJ, Eytan GD, Assaraf YG (1996) Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem 271:3163–3171CrossRefPubMed
45.
Stark M, Assaraf YG (2017) Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells. Oncotarget 8:49973–49987CrossRefPubMedPubMedCentral
46.
Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zanten I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, Van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, Jansen G (2008) Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112:2489–2499.CrossRefPubMed
47.
Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813–823CrossRefPubMed
48.
Raijmakers R, Berkers CR, de Jong A, Ovaa H, Heck AJ, Mohammed S (2008) Automated online sequential isotope labeling for protein quantitation applied to proteasome tissue-specific diversity. Mol Cell Proteomics 7:1755–1762CrossRefPubMedPubMedCentral
49.
Oerlemans R, van der Heijden J, Vink J, Dijkmans BA, Kaspers GJ, Lems WF, Scheffer GL, Ifergan I, Scheper RJ, Cloos J, Assaraf YG, Jansen G (2006) Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids. Arthritis Rheum 54:557–568CrossRefPubMed
50.
Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galardy PJ (2005) Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods 2:357–362CrossRefPubMed
51.
Berkers CR, van Leeuwen FW, Groothuis TA, Peperzak V, van Tilburg EW, Borst J, Neefjes JJ, Ovaa H (2007) Profiling proteasome activity in tissue with fluorescent probes. Mol Pharm 4:739–748CrossRefPubMed
52.
Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, Weinstein JN, Gottesman MM (2004) Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6:129–137CrossRefPubMed
53.
Franke NE, Niewerth D, Assaraf YG, van Meerloo J, Vojtekova K, Van Zantwijk CH, Zweegman S, Chan ET, Kirk CJ, Geerke DP, Schimmer AD, Kaspers GJ, Jansen G, Cloos J (2012) Impaired bortezomib binding to mutant beta5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia 26:757–768CrossRefPubMed
54.
Franke NE, Kaspers GL, Assaraf YG, van Meerloo J, Niewerth D, Kessler FL, Poddighe PJ, Kole J, Smeets SJ, Ylstra B, Bi C, Chng WJ, Horton TM, Menezes RX, Musters RJ, Zweegman S, Jansen G, Cloos J (2016) Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors. Oncotarget 7:74779–74796CrossRefPubMedPubMedCentral
55.
Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT (2005) Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 65:3828–3836CrossRefPubMed
56.
Groll M, Berkers CR, Ploegh HL, Ovaa H (2006) Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 14:451–456CrossRefPubMed
57.
Kessler BM, Tortorella D, Altun M, Kisselev AF, Fiebiger E, Hekking BG, Ploegh HL, Overkleeft HS (2001) Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits. Chem Biol 8:913–929CrossRefPubMed
58.
Unno M, Mizushima T, Morimoto Y, Tomisugi Y, Tanaka K, Yasuoka N, Tsukihara T (2002) The structure of the mammalian 20S proteasome at 2.75 a resolution. Structure 10:609–618CrossRefPubMed
59.
Huber EM, Heinemeyer W, Groll M (2015) Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914. Structure 23:407–417CrossRefPubMed
60.
Minderman H, Zhou Y, O'loughlin KL, Baer MR (2007) Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemother Pharmacol 60:245–255CrossRefPubMed
61.
Verbrugge SE, Assaraf YG, Dijkmans BA, Scheffer GL, Al M, den Uyl D, Oerlemans R, Chan ET, Kirk CJ, Peters GJ, Van der Heijden JW, de Gruijl TD, Scheper RJ, Jansen G (2012) Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther 341:174–182CrossRefPubMed
Metadata
Title
Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide
Authors
Ruud Oerlemans
Celia R. Berkers
Yehuda G. Assaraf
George L. Scheffer
Godefridus J. Peters
Sue Ellen Verbrugge
Jacqueline Cloos
Jerry Slootstra
Rob H. Meloen
Robert H. Shoemaker
Ben A. C. Dijkmans
Rik J. Scheper
Huib Ovaa
Gerrit Jansen
Publication date
01-10-2018
Publisher
Springer US
Published in
Investigational New Drugs / Issue 5/2018
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-018-0569-x

Other articles of this Issue 5/2018

Investigational New Drugs 5/2018 Go to the issue

PHASE I STUDIES

Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study

SHORT REPORT

Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report

PRECLINICAL STUDIES

Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor

PHASE II STUDIES

Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world

SHORT REPORT

GLP overexpression is associated with poor prognosis in Chronic Lymphocytic Leukemia and its inhibition induces leukemic cell death

PHASE I STUDIES

A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits